Eptinezumab Combined with Patient Education for Chronic Migraine and Medication-Overuse Headache: Insights from the RESOLUTION Trial

Highlights

• The RESOLUTION trial provides Class I evidence that eptinezumab (100 mg IV) combined with a Brief Educational Intervention (BEI) is superior to placebo plus BEI in reducing monthly migraine days (MMDs) in patients with Chronic Migraine (CM) and Medication-Overuse Headache (MOH).
• Significant reduction in disease burden was observed as early as weeks 1–4 and sustained through the 12-week placebo-controlled period.
• Key secondary endpoints, including reductions in monthly headache days, acute medication use, and average pain intensity, were all statistically significant.
• The safety profile of eptinezumab in this complex CM/MOH cohort was consistent with previous clinical trials, showing no new safety signals.

Background

Chronic migraine (CM) affects approximately 1% to 2% of the global population and is often complicated by medication-overuse headache (MOH). MOH is defined by the International Classification of Headache Disorders (ICHD-3) as headache occurring on 15 or more days per month in a patient with a pre-existing headache disorder, resulting from the regular overuse of acute or symptomatic headache medication for more than three months.

The management of patients with concurrent CM and MOH is notoriously difficult. Traditionally, treatment strategies involved the withdrawal of the overused medication—often a distressing process for the patient—followed by the initiation of preventive therapy. However, the optimal sequence of intervention (withdrawal vs. immediate prevention) and the role of integrated patient education have been subjects of ongoing clinical debate.

Eptinezumab is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, preventing it from binding to its receptor. Unlike subcutaneous CGRP inhibitors, eptinezumab is administered intravenously, achieving 100% bioavailability immediately after infusion. This pharmacokinetic profile suggests the potential for a rapid onset of action, which is particularly desirable in the high-burden CM/MOH population. The RESOLUTION trial was designed to evaluate whether eptinezumab, when paired with a standardized brief educational intervention (BEI), could effectively reduce the migraine burden in this challenging patient group.

Key Content

Study Design and Patient Population

The RESOLUTION trial (NCT05452239) was a Phase 4, multicenter, randomized, double-blind, placebo-controlled study conducted across 76 specialist clinics in 11 countries. The study enrolled 608 adults diagnosed with both CM and MOH. Participants were randomized 1:1 to receive either a single 100 mg IV dose of eptinezumab or a placebo IV.

Crucially, both groups received a standardized Brief Educational Intervention (BEI). The BEI aimed to inform patients about the risks of medication overuse, the mechanisms of MOH, and the importance of adhering to the treatment plan. This design allowed investigators to isolate the pharmacological effect of eptinezumab above and beyond the well-documented benefits of patient education alone.

Primary Outcome: Rapid Reduction in Migraine Days

The primary endpoint was the mean change from baseline in monthly migraine days (MMDs) during the first 4 weeks post-infusion. The results were highly significant:

• Eptinezumab + BEI Group: Experienced a mean reduction of 6.9 MMDs.
• Placebo + BEI Group: Experienced a mean reduction of 3.7 MMDs.
• Treatment Difference: -3.2 (95% CI -4.2 to -2.2; p < 0.0001).

The rapid response within the first month highlights the utility of the intravenous delivery route in providing immediate therapeutic levels of the antibody, potentially interrupting the cycle of medication overuse earlier than other preventive modalities.

Secondary Endpoints and Disease Burden

All multiplicity-controlled secondary endpoints favored the eptinezumab group. These included:

• Monthly Headache Days (MHDs): Significant reduction compared to placebo.
• Acute Medication Use: Participants receiving eptinezumab showed a markedly greater decrease in the number of days per month they required acute migraine treatments (e.g., triptans, NSAIDs, or simple analgesics).
• Pain Intensity: Average daily pain scores were significantly lower in the eptinezumab group compared to the placebo group.
• MOH Resolution: A higher proportion of patients in the eptinezumab group no longer met the ICHD-3 criteria for MOH and CM by the end of the 12-week period.

The data indicate that the clinical gains achieved in the first four weeks were not only maintained but often improved upon throughout the 12-week observation period.

Safety and Tolerability

The proportion of patients experiencing treatment-emergent adverse events (TEAEs) was comparable between the eptinezumab (41.9%) and placebo (36.9%) groups. Most TEAEs were mild to moderate in severity. Common reports included nasopharyngitis and infusion-site reactions, which are consistent with the established safety profile of the CGRP monoclonal antibody class. No new safety signals or serious drug-related adverse events were identified in this Phase 4 trial.

Expert Commentary

The Synergy of Education and Pharmacotherapy

The RESOLUTION trial is landmark in its inclusion of a standardized educational component for both the active and control arms. It is well known that patient education and “simple advice” can lead to improvements in MOH; indeed, the placebo group’s reduction of 3.7 MMDs is substantial. However, the additional 3.2-day reduction provided by eptinezumab underscores that while education is a cornerstone of MOH management, pharmacological intervention with a CGRP ligand inhibitor provides superior control of the underlying migraine pathology.

Mechanistic Considerations in MOH

Medication overuse is thought to drive a state of central sensitization and glial activation, lowering the threshold for migraine triggers. CGRP is a key mediator of this sensitization. By neutralizing CGRP ligands with high affinity and immediate systemic availability via IV administration, eptinezumab may effectively “reset” the trigeminovascular system, allowing patients to more successfully adhere to the behavioral changes suggested in the educational intervention.

Clinical Applicability

For the practicing neurologist, these findings suggest that eptinezumab is a powerful tool for the management of the most severely affected migraine patients. The Class I evidence supports a shift away from traditional “withdrawal-first” strategies toward a strategy of “concurrent prevention and education.” This approach may reduce the suffering associated with acute medication withdrawal and improve long-term outcomes for patients with CM and MOH.

Conclusion

The RESOLUTION trial reinforces the efficacy and safety of eptinezumab in the management of chronic migraine complicated by medication overuse. By combining rapid-acting intravenous CGRP inhibition with standardized patient education, clinicians can achieve significant and sustained reductions in migraine burden and acute medication reliance. Future research should explore the long-term (beyond 12 weeks) remission rates of MOH in patients treated with this combination and investigate whether such early, aggressive intervention can prevent the progression of CM to even more refractory states.

References

• Jensen RH, Lundqvist C, Schytz HW, et al. Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial. Neurology. 2026;106(8):e214863. PMID: 41886713.
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of eptinezumab for the preventive treatment of chronic migraine: Results from the PROMISE-2 phase 3 randomized clinical trial. Cephalalgia. 2019;39(10):1275-1285. PMID: 31302974.
• Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12(10):575-583. PMID: 27581551.